水杨酸-(2-硝基苯胺) | 37183-26-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 水杨酸-(2-硝基苯胺)
• 英文名称: salicylic acid-(2-nitro-anilide)
• 英文别名: Salicylsaeure-(2-nitro-anilid)；Salicylsaeure-<2-nitro-anilid>；Salicylsaeure-2-nitroanilid；2'-Nitrosalicylanilid；2-hydroxy-N-(2-nitrophenyl)benzamide
• CAS: 37183-26-9
• 化学式: C₁₃H₁₀N₂O₄
• mdl: MFCD00206014
• 分子量: 258.233
• InChiKey: BOGCXDSQUVFRGC-UHFFFAOYSA-N

物化性质

• 沸点：
  363.3±27.0 °C(Predicted)
• 密度：
  1.446±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  水杨酸-(2-硝基苯胺) 在 potassium carbonate 、 copper(II) sulfate 、 sodium ascorbate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 6.0h， 生成 2-((1-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-(2-nitrophenyl)benzamide
  参考文献：
  名称：

  作为有效ABCB1抑制剂的JL-A7衍生物的合成和生物学评估

  摘要：

  癌症化学疗法失败通常是由于ATP结合盒（ABC）转运蛋白（尤其是ABCB1）的过表达，导致各种与结构和药理无关的药物外排。ABCB1抑制剂可以逆转多药耐药性（MDR）现象。现在，以三唑-N-乙基-四氢异喹啉骨架为基础的JL-A7作为先导化合物，设计合成了18种化合物。对位取代产生了对ABCB1的高活性。此外，化合物5可以有效地阻断ABCB1的药物外流功能并增加抗癌药物的积累，从而在MDR细胞中达到有效的治疗浓度。

  DOI：

  10.1016/j.bmc.2017.06.015
• 作为产物：
  描述：

  sodium O-acetylsalicylate 在 氯化亚砜 作用下， 以 苯 为溶剂， 反应 18.33h， 生成 水杨酸-(2-硝基苯胺)
  参考文献：
  名称：

  New 5-substituted-1-(2-hydroxybenzoyl)-benzotriazoles, potassium channel activators. IV

  摘要：

  This paper reports the synthesis of a series of new 5-substituted-1-(2-hydroxybenzoyl)-benzotriazoles, which have been tested for their activity as possible activators of potassium channels. In rat aortic rings, the 'opened' derivatives 1a-f, intermediates of synthesis, showed vasorelaxing properties, with appreciable values of potency. However, the most remarkable effects were recorded for the 2-hydroxybenzoylbenzotriazoles 3a-f, which showed full vasorelaxing efficacy and high potency values. The introduction of a 2-hydroxybenzyl substituent in the 1 position of the benzotriazole ring (compound 7) strongly decreased the activity, showing the importance of the electron-acceptor carbonyl function. The best compound, 3b, was further investigated, in order to evaluate the possible mechanism of action involved in the vasodilator activity. In the vascular model, different potassium channel blockers inhibited the effects of the compound, and an increase of the levels of membrane depolarisation induced a significant reduction of the recorded responses. Compound 3b was also tested in a model of isolated rat heart, retroperfused through the aorta and submitted to a global ischemia/reperfusion cycle. In such an experimental condition, 3b showed an interesting cardioprotective activity. All the above observations are in agreement with the hypothesis of a mechanism linked to the activation of potassium channels. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01146-6

文献信息

• Mensching, Justus Liebigs Annalen der Chemie, 1881, vol. 210, p. 345
  作者：Mensching

  DOI：——

  日期：——
• Huebner; Menschning, Justus Liebigs Annalen der Chemie, 1881, vol. 210, p. 345
  作者：Huebner、Menschning

  DOI：——

  日期：——
• ORZALESI G.; SELLERI R.; CALDINI O.; INNOCENTI F.; MAGLI M., BOLL. CHIM. FARM. <BCFA-AI>, 1975, 114, NO 8, 445-449
  作者：ORZALESI G.、 SELLERI R.、 CALDINI O.、 INNOCENTI F.、 MAGLI M.

  DOI：——

  日期：——
• MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS
  申请人：SmithKline Beecham Corporation

  公开号：EP1100484A1

  公开（公告）日：2001-05-23
• [EN] MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS DES MONOCYTES MACROPHAGES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2000003704A1

  公开（公告）日：2000-01-27

  Macrophage scavenger receptor antagonists are provided. Methods of treating cardiovacular disease comprising administration of the present compounds are also provided. The present compounds inhibit lipid accumulation within macrophage-derived foam cells.